IP Library › Granted Patent US 12,252,541
Granted Patent B2
US 12,252,541 · App. 17/053,256 · Granted Mar 18, 2025

Anti-BCMA antibody and use thereof

Inventors: Kyungjin Park (Gyeonggi-Do, KR); Hyejin Chung (Gyeonggi-do, KR); Kyeongsu Park (Gyeonggi-do, KR); Yangsoon Lee (Gyeonggi-do, KR); Mikyung Chang (Gyeonggi-do, KR); Jaehyoung Jeon (Gyeonggi-do, KR); Youngkwang Kim (Gyeonggi-do, KR); Junhyun Jeong (Gyeonggi-do, KR); Jiseon Yoo (Gyeonggi-do, KR); Yeunju Kim (Gyeonggi-do, KR); Donghoon Yeom (Gyeonggi-do, KR); Eunjung Kim (Gyeonggi-do, KR); Bora Lee (Gyeonggi-do, KR); Jinwon Jung (Gyeonggi-do, KR)
Assignee: ABL BIO INC.
C07K16/2878A61K47/6849A61P35/00C07K16/30A61K2039/505C07K2317/33C07K2317/565C07K2317/732C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,541
App. No.
17/053,256
Granted
Mar 18, 2025
Kind
B2
Abstract

Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Claims (112)

1. An antibody or an antigen-binding fragment thereof that binds to B-cell maturation antigen (BCMA), wherein said antibody or antigen-binding fragment comprises:

(a) a complementarity-determining region-H1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 27,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 35,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 46,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 56,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 66, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 75;

(b) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;

(c) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 58,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;

(d) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 30,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 38,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 49,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 59,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 78;

(e) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;

(f) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 76;

(g) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;

(h) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 57,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;

(i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;

(j) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 120,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;

(k) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 122;

(l) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 28,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 36,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 47,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 121,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 67, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 123;

(m) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 124,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77,

(n) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 125,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;

(o) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 126,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77;

(p) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 127,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence SEQ ID NO: 77; and

(q) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 29,

a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 37,

a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 48,

a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 128,

a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 68, and

a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 77.

2. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5 to 8.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment comprises a light chain variable region-includes comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 16 to 19 and 107 to 119.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment inhibits binding between BCMA and a substance specifically binding to BCMA.

5. The antibody or antigen-binding fragment thereof of claim 4 , wherein the substance specifically binding to BCMA is BAFF (B-cell activating factor belonging to the tumor necrosis factor family), APRIL (a proliferation inducing ligand), or a combination thereof.

6. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antigen-binding fragment is scFv, (scFv) 2 , Fv, Fab, Fab′, F(ab′) 2 , or a combination thereof.

7. The antibody or the antigen-binding fragment thereof of claim 1 , wherein the antibody or the antigen-binding fragment is conjugated with an anti-cancer drug.

8. A pharmaceutical composition, comprising the antibody or the antigen-binding fragment thereof of claim 1 .

9. A method for treating multiple myeloma in an individual in need thereof, the method comprising:

administering the antibody or the antigen-binding fragment thereof of claim 1 to the individual.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 5, 2020
From: PARK, KYUNGJIN; CHUNG, HYEJIN; PARK, KYEONGSU; LEE, YANGSOON; CHANG, MIKYUNG; JEON, JAEHYOUNG; KIM, YOUNGKWANG; JEONG, JUNHYUN; YOO, JISEON; KIM, YEUNJU; YEOM, DONGHOON; KIM, EUNJUNG; LEE, BORA; JUNG, JINWON
To: ABL BIO INC.
Reel/Frame 054289/0304 →
Priority Claims (1)
KR 10-2018-0073320 · Jun 26, 2018 · national
Continuity (1)
Related Publication 20210284749A1 · Sep 16, 2021
References Cited (30)
US 9243058B2 · Armitage et al. · 2016 [cited by applicant]
US 20130273055A1 · Borges et al. · 2013 [cited by applicant]
US 20160297885A1 · Kuo et al. · 2016 [cited by applicant]
US 20170051068A1 · Pillarisetti et al. · 2017 [cited by applicant]
US 20170233484A1 · Sussman · 2017 [cited by examiner]
US 20170306036A1 · Vu et al. · 2017 [cited by applicant]
US 20180118842A1 · Brentjens et al. · 2018 [cited by applicant]
US 20190161552A1 · Kalled et al. · 2019 [cited by applicant]
CN 107206076A · 2017 [cited by applicant]
JP 2017532290A · 2017 [cited by applicant]
KR 1020110126740A · 2011 [cited by applicant]
WO WO2012066058A1 · 2012 [cited by applicant]
WO WO2016090327A2 · 2016 [cited by applicant]
WO WO2018083204A1 · 2018 [cited by applicant]
Casset et al. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochem Biophys Res Comm 307: 198-205, 2003. [cited by examiner]
Chen et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 293: 865-881, 1999. [cited by examiner]
De Pascalis et al. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. J I… [cited by examiner]
Holm et al. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Mol Immunol 44: 1075-1084, 2007. [cited by examiner]
Maccallum et al. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol 262: 732-745, 1996. [cited by examiner]
Paul, William E., Fundamental Immunology, 3rd Edition, Raven Press, New York, Chapt. 8, pp. 292-295 (1993). [cited by examiner]
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci USA 79: 1979-1983, 1982. [cited by examiner]
White et al. Cancer prevention for hte next generation. J Adolesc Health 52: S1-S7, 2013. [cited by examiner]
Zhang et al. Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle. mAbs 7(1): 42-52, 2015 (published online Nov. 21, 2014). [cited by examiner]
Oden Felix et al: “Potent anti-tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma”, Molecular Oncology, vol. 9, No. 7 , pp. 1348-1358, XP029252531, 2015. [cited by applicant]
Dissertation: “Generation of an antibody targeting B cell maturation antigen for the treatment of multiple myeloma and autoimmune diseases”, Apr. 1, 2014 (Apr. 1, 2014), XP055195743. [cited by applicant]
Kevin M. Friedman et al: “Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells”, Human Gene Therapy, vol. 29,… [cited by applicant]
Extended European Search Report from corresponding EP Patent Application No. 19826406.1, dated Nov. 23, 2021. [cited by applicant]
Office Action from corresponding Japanese Patent Application No. 2020-559502, dated May 1, 2023. [cited by applicant]
Sanchez, et al. (2016) “Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma.”, Myeloma Clinical Cancer Research, 22(13):3383-3397. [cited by applicant]
International Search Report (ISR) issued for corresponding International Patent Application No. PCTKR2019007727, dated Sep. 24, 2019, with English Translation. [cited by applicant]
Cited By (1)
US 12,577,314